Show simple item record

dc.contributor.authorRichardson, E
dc.contributor.authorStockwell, SR
dc.contributor.authorLi, H
dc.contributor.authorAherne, W
dc.contributor.authorCuomo, ME
dc.contributor.authorMittnacht, S
dc.date.accessioned2018-05-24T11:02:20Z
dc.date.issued2012-02-27
dc.identifier.citationPloS one, 2012, 7 (2), pp. e31627 - ?
dc.identifier.issn1932-6203
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1689
dc.identifier.eissn1932-6203
dc.identifier.doi10.1371/journal.pone.0031627
dc.description.abstractDNA damage activates checkpoint controls which block progression of cells through the division cycle. Several different checkpoints exist that control transit at different positions in the cell cycle. A role for checkpoint activation in providing resistance of cells to genotoxic anticancer therapy, including chemotherapy and ionizing radiation, is widely recognized. Although the core molecular functions that execute different damage activated checkpoints are known, the signals that control checkpoint activation are far from understood. We used a kinome-spanning RNA interference screen to delineate signalling required for radiation-mediated retinoblastoma protein activation, the recognized executor of G(1) checkpoint control. Our results corroborate the involvement of the p53 tumour suppressor (TP53) and its downstream targets p21(CIP1/WAF1) but infer lack of involvement of canonical double strand break (DSB) recognition known for its role in activating TP53 in damaged cells. Instead our results predict signalling involving the known TP53 phosphorylating kinase PRPK/TP53RK and the JNK/p38MAPK activating kinase STK4/MST1, both hitherto unrecognised for their contribution to DNA damage G1 checkpoint signalling. Our results further predict a network topology whereby induction of p21(CIP1/WAF1) is required but not sufficient to elicit checkpoint activation. Our experiments document a role of the kinases identified in radiation protection proposing their pharmacological inhibition as a potential strategy to increase radiation sensitivity in proliferating cancer cells.
dc.formatPrint-Electronic
dc.format.extente31627 - ?
dc.languageeng
dc.language.isoeng
dc.publisherPUBLIC LIBRARY SCIENCE
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectCell Line, Tumor
dc.subjectHumans
dc.subjectDNA Damage
dc.subjectMAP Kinase Kinase 4
dc.subjectGreen Fluorescent Proteins
dc.subjectAntineoplastic Agents
dc.subjectSignal Transduction
dc.subjectCell Cycle
dc.subjectG1 Phase
dc.subjectCell Survival
dc.subjectGene Expression Regulation, Neoplastic
dc.subjectRNA Interference
dc.subjectGenes, Reporter
dc.subjectModels, Genetic
dc.subjectTumor Suppressor Protein p53
dc.subjectCyclin-Dependent Kinase Inhibitor p21
dc.titleMechanism-based screen establishes signalling framework for DNA damage-associated G1 checkpoint response.
dc.typeJournal Article
dcterms.dateAccepted2012-01-16
rioxxterms.versionofrecord10.1371/journal.pone.0031627
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2012-01
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfPloS one
pubs.issue2
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Anti Oncogene
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Anti Oncogene
pubs.publication-statusPublished
pubs.volume7
pubs.embargo.termsNo embargo
icr.researchteamAnti Oncogene
dc.contributor.icrauthorMittnacht, Sibylle


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0